Quintiles Announces New Brand Identity
Quintiles (Research Triangle Park, NC) has launched a new positioning and brand identity.
“The New Health is our description of the rapidly changing world of biopharma,” said Quintiles Chief Operating Officer John Ratliff in a company press release. “We define the New Health in a number of ways, both as a journey and as a destination. The term encapsulates the risks and opportunities biopharma faces in today’s changing economic and healthcare settings.”
Quintiles’ new positioning includes the introduction of a unified brand, a new visual system, an updated logo, and new company tag line (“Navigating the New Health"), all designed to communicate the company’s business approach and the transformative changes it is making within the biopharmaceutical industry.
The new brand identity is being launched behind an advertising campaign that communicates a patient-centric vision of change. The first wave of repositioning will be launched in online advertising and will be followed by a sustained trade and business media print campaign across the United States, Europe, and Japan.
For a video on the New Health, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
